Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 6/20 | 0.37 |
| ▸ | CTSL | P07711 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | MTTP | P55157 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624421 | 0.94 | CTSL (0.44) | CTSKCTSLCTSSPDK2 | |
| SCHEMBL4367886 | 0.90 | CTSK (0.43) | CTSKCTSLNPC1RAB9ATAS1R3 | |
| SCHEMBL4367894 | 0.90 | CTSK (0.43) | CTSKCTSLNPC1RAB9ATAS1R3 | |
| SCHEMBL4375019 | 0.88 | CTSL (0.40) | ALDH1A1CTSKCTSLNPC1RAB9A | |
| SCHEMBL13624306 | 0.88 | CTSL (0.42) | CTSKCTSLTAS1R3TAS1R1 | |
| SCHEMBL13624172 | 0.87 | TAS1R3 (0.47) | CTSKCTSLNPC1RAB9ACTSS | |
| SCHEMBL13624419 | 0.87 | CTSL (0.39) | CTSKCTSLNPC1RAB9APDK2 | |
| SCHEMBL13634972 | 0.87 | CTSL (0.41) | ALDH1A1CTSKCTSLTAS1R3TAS1R1 | |
| SCHEMBL13624422 | 0.86 | CTSL (0.38) | ALDH1A1CTSKCTSLNPC1RAB9A | |
| SCHEMBL4371069 | 0.85 | CTSL (0.44) | CTSKCTSLCTSSTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | ALDH1A1 2506/4885LMNA 4790/4885CPT2 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.